The clinical potential of low-level C-peptide secretion

Expert Review of Molecular Diagnostics

Volumn 16, Issue 9, 2016, Pages 933-940

  Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

beta cell function; beta cell preservation; C peptide; complications; hypoglycaemia; immune interventions; keto acidosis; type 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C;

ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN DETERMINATION; PROTEIN SECRETION; QUALITY OF LIFE; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

C-PEPTIDE; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS;

EID: 84978759553     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1080/14737159.2016.1210513     Document Type: Article

References (81)

1. J.Ludvigsson, U.Samuelsson Continuous insulin infusion (CSII) or modern type of multiple daily injections (MDI) in diabetic children and adolescents a critical review on a controversial issue. Pediatr Endocrinol Rev. 2007;5(2):666–678. Review.
2. M.L.Misso, K.J.Egberts, M.Page, et al. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010;1:CD005103.
3. C.Quirós, M.Giménez, P.Ríos, et al. Long-term outcome of insulin pump therapy:reduction of hypoglycaemia and impact on glycaemic control. Conget I. Diabet Med. 2016. doi:10.1111/dme.13094. [Epub ahead of print].
4. B.Bohn, W.Kerner, J.Seufert, et al.; DPV-initiative. Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014:analysis of real-life data from the DPV registry from Germany and Austria. Diabetes Res Clin Pract. 2016;115:31–38.
5. W.V.Tamborlane, R.W.Beck, B.W.Bode, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464–1476. Epub 2008 Sep 8. doi:10.1056/NEJMoa0805017.
6. I.B.Jacobsen, J.E.Henriksen, O.Hother-Nielsen, et al. Evidence-based insulin treatment in type 1 diabetes mellitus. Diabetes Res Clin Pract. 2009;86(1):1–10. Epub 2009 Aug 3. Review. doi:10.1016/j.diabres.2009.05.020.
7. A.Siebenhofer, J.Plank, A.Berghold, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;2:CD003287. Review.
8. M.Monami, N.Marchionni, E.Mannucci. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009;11(4):372–378.
9. A.C.C.Sanches, C.J.Correr, R.Venson, et al. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons. Diabetes Res Clin Pract. 2011;94(3):333–339.
10. D.R.Owens, G.Matfin, L.Monnier. Basal insulin analogues in the management of diabetes mellitus:what progress have we made? Diabetes Metab Res Rev. 2014;30(2):104–119.
11. M.J.Rewers, K.Pillay, C.de Beaufort, et al.; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;15 Suppl 20:102–114.
12. American Diabetes Association. Glycemic targets. Diabetes Care. 2015;38 Suppl(Supplement 1):S33–S40.
13. K.Eeg-Olofsson, J.Cederholm, P.M.Nilsson, et al. Glycemic control and cardiovascular disease in 7,454 patients with type 1 diabetes:an observational study from the Swedish National Diabetes Register (NDR). Diabetes Care. 2010;33(7):1640–1646.
14. A.Peterson, L.Hanberger, K.Akesson, et al. Improved results in paediatric diabetes care using a quality registry in an improvement collaborative:a case study in Sweden. PLoS One. 2014;9(5):e97875.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
16. M.Bojestig, H.J.Arnqvist, G.Hermansson, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994;330:15–18.• First study showing the importance of good metabolic control for prevention of late diabetic complications in a general patient population.
17. M.Nordwall, M.Abrahamsson, M.Dhir, et al. Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy:the VISS Study (Vascular Diabetic Complications in Southeast Sweden). Diabetes Care. 2015;38(2):308–315.
18. M.Lind, A.-M.Svensson, A.Rosengren. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2015;372(9):880–881.• Still with nmodern and quite successful treatment mortality is increased in patients with Type 1 diabetes.
19. S.J.Livingstone, D.Levin, H.C.Looker, et al.; Scottish Diabetes Research Network epidemiology group; Scottish Renal Registry. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 2015;313(1):37–44.
20. D.F.Steiner, D.Cunningham, L.Spigelman, et al. Insulin biosynthesis:evidence for a precursor. Science. 1967;157:697–700.
21. J.Ludvigsson, L.Heding:. Abnormal proinsulin/C-peptide ratio in juvenile diabetes. Acta Diabetol Lat. 1982;19:351–358.
22. R.A.Oram, T.J.McDonald, B.M.Shields, et al.; UNITED Team. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care 2015;38(2):323–328.
23. L.Wang, N.F.Lovejoy, D.L.Faustman. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care. 2012;35(3):465–470.•• Many patients have some residual beta cells which function still after decades with Type 1 diabetes.
24. C.J.Greenbaum, T.Mandrup-Poulsen, P.F.McGee, et al.; The Type 1 Diabetes TrialNet Research Group and The European C-peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care. 2008;31:1966–1971.•• Mixed Meal Tolerence Test is the most physiological way of stimulating the beta cells for evaluation of function.
25. J.L.Sherr, T.Ghazi, A.Wurtz, et al. Characterization of residual β cell function in long-standing type 1 diabetes. Diabetes Metab Res Rev. 2014;30(2):154–162.
26. U.Samuelsson, J.Ludvigsson, G.Sundkvist. Islet cell antibodies (ICA), insulin autoantibodies (IAA), islet cell surface antibodies (ICSA) and C-peptide in 1031 school children in a population with a high background incidence of IDDM. Diabetes Res Clin Pract. 1994;26:155–162.
27. R.E.J.Besser, J.Ludvigsson, A.G.Jones, et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care. 2011;34:607–609.• Urinary C-peptide is an alternative for evaluation of beta cell function.
28. J.Ludvigsson, A.Carlsson, G.Forsander, et al. C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes. 2012;13(1):45–50. Epub 2011 Sep 13. doi:10.1111/j.1399-5448.2011.00807.x.
29. R.A.Insel, J.L.Dunne, M.A.Atkinson, et al. Staging presymptomatic type 1 diabetes:a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964–1974. doi:10.2337/dc15-1419.
30. M.Nordwall, J.Ludvigsson. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years. Diabetes Metab Res Rev. 2008;24:472–479.
31. M.L.Max Andersen, L.B.Nielsen, J.Svensson, et al. Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27 yr. Pediatr Diabetes. 2014;15(5):345–354.
32. J.Ludvigsson, A.Carlsson, A.Deli, et al. Decline of C-peptide during the first year after diagnosis of Type 1 diabetes in children and adolescents. Diabetes Res Clin Pract. 2013;100(2):203–209.• C-peptide, both at diagnosis and the following decline differes with age.
33. J.B.Bollyky, P.Xu, A.J.Butte, et al. Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective. Type 1 Diabetes TrialNet Study Group. Diabetes Metab Res Rev. 2015;31(6):588–594.
34. L.A.DiMeglio, P.Cheng, R.W.Beck, et al. Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Group. Pediatr Diabetes. 2016;17(4):237–243.
35. M.Knip, A.Sakkinen, N.P.Huttunen, et al. Postinitial remission in diabetic children–an analysis of 178 cases. Acta Paediatr Scand. 1982;71:901–908.
36. J.Ludvigsson. Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset:relationship to B-cell function and partial remission. Diabetologia. 1984;26:138–141.
37. B.Buckingham, P.Cheng, R.W.Beck, et al.; Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia. 2015;58(6):1167–1174.•• Already minor residual beta cell function improves metabolic control, reduces blood glucose fluctuations.
38. C.R.Stiller, J.Dupré, M.Gent, et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science. 1984;223(4643):1362–1367.
39. K.C.Herold, W.Hagopian, J.A.Auger, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1692–1698.
40. B.Keymeulen, E.Vandemeulebroucke, A.G.Ziegler, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352(25):2598–2608.
41. N.Sherry, W.Hagopian, J.Ludvigsson, et al.; Protege Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protege study):1-year results from a randomised, placebo-controlled trial. Lancet. 2011;378(9790):487–497.
42. W.Hagopian, R.J.FerryJr, N.Sherry, et al.; Protégé Trial Investigators. Teplizumab preserves C-peptide in recent-onset type 1 diabetes:two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901–3908. 33.
43. J.Ludvigsson, M.Faresjö, M.Hjorth, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359(18):1909–1920.
44. J.Ludvigsson. Combination therapy for preservation of beta cell function in Type 1 diabetes:new attitudes and strategies are needed! Immunol Lett. 2014;159(1–2):30–35. Epub 2014 Feb 24. Review. doi:10.1016/j.imlet.2014.02.006.
45. J.Ludvigsson. Therapies to preserve β-cell function in type 1 diabetes. Drugs. 2016;76(2):169–185.
46. T.Anderbro, S.Amsberg, U.Adamson, et al. Fear of hypoglycaemia in adults with Type 1 diabetes. Diabet Med. 2010;27(10):1151–1158. Review.
47. T.Danne, T.Battelino, P.Jarosz-Chobot, et al.; PedPump Study Group. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes:experience of the PedPump Study in 17 countries. Diabetologia. 2008;51(9):1594–1601.
48. S.Madsbad, K.G.Alberti, C.Binder, et al. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J. 1979;2:1257–1259.
49. J.Komulainen, R.Lounamaa, M.Knip, et al. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell function. Childhood Diabetes in Finland Study Group. Arch Dis Child. 1996;75:410–415.
50. J.Ostman, M.Landin-Olsson, C.Torn, et al. Ketoacidosis in young adults is not related to the islet antibodies at the diagnosis of Type 1 diabetes mellitus–a nationwide study. Diabet Med. 2000;17:269–274.
51. M.W.Steffes, S.Sibley, M.Jackson, et al. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care. 2003;26:832–836.•• Already a slight residual beta cell function protects against complications.
52. A.Barker, A.Lauria, N.Schloot, et al. Age-dependent decline of β-cell function in type 1 diabetes after diagnosis:a multi-centre longitudinal study. Diabetes Obes Metab. 2014;16(3):262–267.
53. W.M.Kuhtreiber, S.L.Washer, E.Hsu, et al. Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabet Med. 2015;32(10):1346–1353.
54. F.Panero, G.Novelli, C.Zucco, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009;32:301–305.
55. S.Sjöberg, M.Gjötterberg, L.Berglund, et al. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus. J Diabetic Complications. 1991;5(1):18–22.
56. H.A.Keenan, J.K.Sun, J.Levine, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes:Joslin Medalist Study. Diabetes. 2010;59:2846–2853.
57. P.Fioretto, M.W.Steffes, D.E.Sutherland, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med. 1998;339:69–75.
58. P.Fiorina, F.Folli, F.Bertuzzi, et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care. 2003;26:1129–1136.
59. P.Luppi, V.Cifarelli, J.Wahren. C-peptide and long-term complications of diabetes. Pediatr Diabetes. 2011;12:276–292.
60. S.Hernández-Díaz, H.O.Adami. Diabetes therapy and cancer risk:causal effects and other plausible explanations. Diabetologia. 2010;53(5):802–808.
61. O.Karlstad, J.Starup-Linde, P.Vestergaard, et al. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013;8(5):333–348. Review.
62. J.Wahren, K.Ekberg, H.Jornvall. C-peptide is a bioactive peptide. Diabetologia. 2007;50:503–509.
63. T.Wallerath, T.Kunt, T.Forst, et al. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide. 2003;9:95–102.
64. R.Scalia, K.M.Coyle, B.J.Levine, et al. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J. 2000;14:2357–2364.
65. T.Kitamura, K.Kimura, K.Makondo, et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia. 2003;46:1698–1705.
66. T.Forst, T.Kunt, T.Pohlmann, et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest. 1998;101:2036–2041.
67. B.L.Johansson, S.Sjoberg, J.Wahren. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia. 1992;35:121–128.
68. M.A.Cotter, K.Ekberg, J.Wahren, et al. Effects of proinsulin C-peptide in experimental diabetic neuropathy:vascular actions and modulation by nitric oxide synthase inhibition. Diabetes. 2003;52:1812–1817.
69. A.Hansen, B.L.Johansson, J.Wahren, et al. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes. 2002;51:3077–3082.
70. T.Forst, D.D.De La Tour, T.Kunt, et al. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond). 2000;98:283–290.
71. P.Luppi, V.Cifarelli, H.Tse, et al. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappa B pathway. Diabetologia. 2008;51:1534–1543.
72. W.Zhang, M.Yorek, C.R.Pierson, et al. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int J Exp Diabetes Res. 2001;2:187–193.
73. A.A.F.Sima, W.Zhang, Z.G.Li, et al. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes. 2004;53:1556–1563.
74. K.Ekberg, T.Brismar, B.L.Johansson, et al. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes. 2003;52:536–541.
75. K.Ekberg, T.Brismar, B.L.Johansson, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care. 2007;30:71–76.
76. B.L.Johansson, K.Borg, E.Fernqvist-Forbes, et al. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia. 1996;39:687–695.
77. B.Samnegard, S.H.Jacobson, G.Jaremko, et al. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int. 2001;60:1258–1265.
78. L.Nordquist, R.Brown, A.Fasching, et al. Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol. 2009;297:1265–1272.
79. L.Nordquist, E.Y.Lai, M.Sjoquist, et al. Proinsulin C-peptide constricts glomerular afferent arterioles in diabetic mice. A potential renoprotective mechanism. Am J Physiol Regul Integr Comp Physiol. 2008;294:R836–R841.
80. B.L.Johansson, A.Kernell, S.Sjoberg, et al. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocrinol Metab. 1993;77:976–981.
81. K.Aaboe, T.Krarup, S.Madsbad, et al. GLP-1:physiological effects and potential therapeutic applications. Diabetes Obes Metab. 2008;10(11):994–1003.